Lupin
LUPIN · Pharma > Pharmaceuticals & Drugs · Chairman: Manju D Gupta · MD: Nilesh Gupta · Listing date: Sept. 11, 2001 · Employees: 18573 · Mumbai · http://www.lupin.com

Stock Price vs Company Growth
1d
0.7%
1w
3.5%
1m
5.4%
3m
0.2%
6m
38.3%
1y
71.8%
5y
23.4%
10y
4.8%
all
18.1%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 2,148 0.7%
1,988
2,312
Company Overview

Sales
21,431 Cr
Growth: 14.6%
Profit after Tax
2,626 Cr
Growth: 16.0%
Large Cap
97,979 Cr
P/E: 37.4x
Industry P/E: 37.3x
Fundamentals

Sales (Cr) ₹ 21,431
Growth 14.6%
EBITDA 21.5%
P/S 4.6x
Dividend 0.4%
P/E 37.4x
Book Value ₹ 349
PEG Ratio 2.6x
ROE 17.7%
P/B 6.1x
Shareholding Pattern

Institutions
Life Insurance Corporation Of India
6.99 %
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund
4.28 %
Government Pension Fund Global
1.21 %
Franklin India Focused Equity Fund
1.13 %
Icici Prudential Life Insurance Company Limited
1.13 %
Promoters
Lupin Investments Pvt Ltd
45.3 %
Manju D Gupta
0.85 %
Nilesh D Gupta
0.2 %
Anuja Gupta
0.16 %
Desh Bandhu Gupta Huf
0.14 %
Others
Rakesh Jhunjhunwala
1.6 %
Nps Trust - A/C Lic Pension Fund Sch-State Govt
1.48 %
Iepf
0.15 %
Increase    Decrease    No change
Company Profile Detailed

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.Products and services offered by the companyGlobal FormulationsActive Pharmaceuticals Ingredients (API)BiotechSpecialty BusinessOver The Counter (OTC)Global Manufacturing & Supply ChainAwards2007: Cardinal Health Conferred Two Awards - The ‘Trade Representative Of The Year’ And The ‘Quality Supplier Award’ To Lupin Pharmaceuticals Inc.
Investors (231)
Followers (55)